Cargando…

Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy

Type 2 diabetes mellitus (T2DM) is an emerging epidemic in Asian countries, especially in India. With the advent of the SGLT2 inhibitor class of drugs demonstrating benefits beyond glycemic control, viz. weight loss, blood pressure reduction, and cardiovascular and renal protection, the management o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Viswanathan, Mithal, Ambrish, Joshi, Shashank R, Aravind, S R, Chowdhury, Subhankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322139/
https://www.ncbi.nlm.nih.gov/pubmed/32612352
http://dx.doi.org/10.2147/DDDT.S221093
_version_ 1783551585157120000
author Mohan, Viswanathan
Mithal, Ambrish
Joshi, Shashank R
Aravind, S R
Chowdhury, Subhankar
author_facet Mohan, Viswanathan
Mithal, Ambrish
Joshi, Shashank R
Aravind, S R
Chowdhury, Subhankar
author_sort Mohan, Viswanathan
collection PubMed
description Type 2 diabetes mellitus (T2DM) is an emerging epidemic in Asian countries, especially in India. With the advent of the SGLT2 inhibitor class of drugs demonstrating benefits beyond glycemic control, viz. weight loss, blood pressure reduction, and cardiovascular and renal protection, the management of T2DM has taken a quantum leap. Remogliflozin etabonate (RE) is the latest addition to the SGLT2 inhibitor class of drugs that have been recently approved in India for the management of T2DM. RE is a potent and selective inhibitor of SGLT2 with the unique distinction of being administered as a prodrug, existence of active metabolites, and short half-life necessitating twice-daily dosing. The Phase III study of RE demonstrated it to be an efficacious and safe agent and non-inferior to the currently available SGLT2 inhibitors. This paper reviews not only the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile of RE but also its molecular and clinical development program. This review has taken into consideration all available published as well as unpublished literature on RE and discusses the individual studies performed during its development for characterization of pharmacological profile.
format Online
Article
Text
id pubmed-7322139
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73221392020-06-30 Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy Mohan, Viswanathan Mithal, Ambrish Joshi, Shashank R Aravind, S R Chowdhury, Subhankar Drug Des Devel Ther Review Type 2 diabetes mellitus (T2DM) is an emerging epidemic in Asian countries, especially in India. With the advent of the SGLT2 inhibitor class of drugs demonstrating benefits beyond glycemic control, viz. weight loss, blood pressure reduction, and cardiovascular and renal protection, the management of T2DM has taken a quantum leap. Remogliflozin etabonate (RE) is the latest addition to the SGLT2 inhibitor class of drugs that have been recently approved in India for the management of T2DM. RE is a potent and selective inhibitor of SGLT2 with the unique distinction of being administered as a prodrug, existence of active metabolites, and short half-life necessitating twice-daily dosing. The Phase III study of RE demonstrated it to be an efficacious and safe agent and non-inferior to the currently available SGLT2 inhibitors. This paper reviews not only the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile of RE but also its molecular and clinical development program. This review has taken into consideration all available published as well as unpublished literature on RE and discusses the individual studies performed during its development for characterization of pharmacological profile. Dove 2020-06-24 /pmc/articles/PMC7322139/ /pubmed/32612352 http://dx.doi.org/10.2147/DDDT.S221093 Text en © 2020 Mohan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mohan, Viswanathan
Mithal, Ambrish
Joshi, Shashank R
Aravind, S R
Chowdhury, Subhankar
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title_full Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title_fullStr Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title_full_unstemmed Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title_short Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
title_sort remogliflozin etabonate in the treatment of type 2 diabetes: design, development, and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322139/
https://www.ncbi.nlm.nih.gov/pubmed/32612352
http://dx.doi.org/10.2147/DDDT.S221093
work_keys_str_mv AT mohanviswanathan remogliflozinetabonateinthetreatmentoftype2diabetesdesigndevelopmentandplaceintherapy
AT mithalambrish remogliflozinetabonateinthetreatmentoftype2diabetesdesigndevelopmentandplaceintherapy
AT joshishashankr remogliflozinetabonateinthetreatmentoftype2diabetesdesigndevelopmentandplaceintherapy
AT aravindsr remogliflozinetabonateinthetreatmentoftype2diabetesdesigndevelopmentandplaceintherapy
AT chowdhurysubhankar remogliflozinetabonateinthetreatmentoftype2diabetesdesigndevelopmentandplaceintherapy